Diese Webseite verwendet Cookies

Diese Seite verwendet Cookies, um Ihnen dieses Angebot leicht zugänglich zu machen, Inhalte zu personalisieren, Ihre Zugriffe auf die Webseite zu analysieren und Ihnen ggf. personalisierte Angebote unterbreiten zu können. Hierzu kann es notwendig sein, dass die Informationen über Ihre Verwendung der Webseite an Partner weitergegeben werden. Diese führen die gesammelten Informationen möglicherweise mit weiteren Daten zusammen, die Sie an anderer Stelle bereitgestellt haben. Eine Weitergabe erfolgt dabei aber nur mit Ihrer Einwilligung und unter Beachtung der datenschutzrechtlichen Vorgaben. Weiterführende Informationen über die hier verwendeten Cookies erfahren Sie in den folgenden Erklärungen zu den jeweiligen Cookies.

Notwendige Cookies helfen dabei, Ihnen die Funktionen der Webseite zugängig zu machen, indem sie Grundfunktionen die zuletzt angesehen Wertpapiere und Ihre Entscheidung für oder gegen die Nutzung der jeweiligen Cookies speichert. Die Webseite wird ohne diese Cookies nicht so funktionieren, wie es geplant ist.

Name Anbieter Zweck Ablauf Typ Verantwortlicher
CookieConsent2111 Moneyspecial Um diese Cookiebar auszublenden. 1 Jahr http Infront Financial Technology GmbH
Die Cookie-Erklärung wurde das letzte Mal am 27.07.2020 von Infront Financial Technology GmbH aktualisiert.
Drucken



diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy




diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy


PR Newswire





Expert recommendations provide crucial guidance to leverage CGM and AID during pregnancy.

SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- The diaTribe Foundation announces the publication of the first international consensus statement on the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) during pregnancy. Published in The Lancet Diabetes & Endocrinology, the document aims to standardize care, improve outcomes, and ease the daily burden of managing type 1 (T1D), type 2 (T2D), and gestational diabetes (GDM) during pregnancy.


Managing diabetes is exceptionally challenging during pregnancy due to hormonal shifts and narrow glucose targets. As CGM and AID become standard of care in diabetes for their ability to improve management, many enter pregnancy already relying on these technologies or adopt them to help navigate this demanding time.

Despite growing use, application of technology has remained disjointed in pregnancy due to a lack of detailed clinical guidance, particularly for T2D and GDM. "Application of Continuous Glucose Monitoring and Automated Insulin Delivery Technologies for Pregnant Women with Type 1 Diabetes, Type 2 Diabetes or Gestational Diabetes Mellitus" was developed by experts across six continents to address this gap.

"It is absolutely possible to have a safe and healthy pregnancy with diabetes, and technologies can help-but these tools are often underutilized due to limited research, few devices approved for use in pregnancy, and a lack of clear guidance," said Dr. Katrien Benhalima, endocrinologist and chair of the expert author group. "Publishing this consensus is a key step to ensuring that maternal healthcare for people with diabetes continues to improve as technologies evolve."

The paper provides 14 specific recommendations, including:

  • Guidance on picking AID systems and adapting settings to meet pregnancy-specific physiological needs, including detailed charts with device-specific recommendations
  • Considerations for technology use during preconception, pregnancy, labor and delivery, and the immediate postpartum period
  • CGM time in range targets specifically for T2D and GDM, expanding upon previous standards set for T1D.

The consensus aims to support key members of the pregnancy care team who may be less familiar with diabetes technologies, including primary care and obstetrics providers, through recommendations based on the latest evidence and clinical experience. By confirming these technologies can be safely used during pregnancy, the authors also hope to increase device access and user confidence.

This initiative was led by The diaTribe Foundation and strengthened by input from 25 leading global bodies, including the American College of Obstetricians and Gynecologists, Breakthrough T1D, European Association for the Study of Diabetes, and World Organization of Family Doctors.

The diaTribe Foundation is dedicated to improving the lives of people with diabetes and advocating for action. We ensure that people have the resources and education needed to thrive with diabetes, bring people with diabetes to the conversation on regulatory issues, connect the field and the diabetes community, and change the narrative around diabetes.

Endorsing organizations:
ADJ Diabetes Brazil
Advanced Technologies & Treatments for Diabetes
American Association of Clinical Endocrinology
American College of Diabetology
American Pharmacists Association
Association of Diabetes Care & Education Specialists
Australasian Diabetes in Pregnancy Society
Australian Diabetes Society
Australian Diabetes Educators Association
Brazilian Diabetes Society
Breakthrough T1D
Centre for Chronic Disease Control (India)
Diabetes Australia
Diabetes India
European Association for the Study of Diabetes
European Board and College of Obstetrics and Gynaecology
Indian College of Obstetricians and Gynaecologists
International Association of Diabetes and Pregnancy Study Groups
International Diabetes Federation
International Federation of Gynaecology and Obstetrics
Japan Diabetes Society
Research Society for the Study of Diabetes India
Society for Obstetric Medicine India
World Organization of Family Doctors

Supported by the American College of Obstetricians and Gynecologists





Cision View original content:https://www.prnewswire.co.uk/news-releases/diatribe-convenes-international-consensus-to-guide-diabetes-technology-use-during-pregnancy-302658755.html





PR Newswire

Zeit Meldung
03.02. PRN: TECNIMONT (MAIRE) AND BAKER HUGHES TO COLLABO
03.02. PRN: MAXHUB präsentiert auf der ISE 2026 bahnbrech
03.02. PRN: Der International AI Safety Report 2026 zeigt
03.02. PRN: Enjin bringt Essence of the Elements auf den
03.02. PRN: Proposed acquisition by US-backed Orion Criti
03.02. PRN: Die RESTART-Studie von Volta Medical liefert
03.02. PRN: HABANOS, S.A. PRÄSENTIERT TRINIDAD CORCEL: EI
03.02. PRN: GRUPPE VON CHAARAT GOLD ANLEIHENINHABERN REAG
03.02. PRN: Arclin schließt Übernahme von The Willamette
03.02. PRN: RoboUP bringt Raccoon 2 SE offiziell auf den
03.02. PRN: EPAM Recognized as Leading Application Servic
03.02. PRN: Lassen Peak beruft Dean Kueter, ehemaliger Ex
03.02. PRN: Lemon Learning übernimmt Aidaxis, um sein Ang
03.02. PRN: Wenn Technik und Traditionen zusammentreffen:
03.02. PRN: VivaTech 2026 Confidence Barometer: Ein Parad
03.02. PRN: VT Markets treibt Wachstum im Jahr 2026 voran
03.02. PRN: Allianz für die Zukunft: tesa, ZEISS, Saint-G
03.02. PRN: LG Innotek Accelerates European Market Penetr
03.02. PRN: Hyundai Mobis bildet globale Allianz für Disp
03.02. PRN: ZEISS, tesa, Saint-Gobain Sekurit und Hyundai
03.02. PRN: DXC von Whitelane Research als einer der drei
03.02. PRN: Das INFINITY 3.0-Modul von DMEGC Solar erreic
03.02. PRN: H55 schließt erfolgreich - zum ersten Mal in
03.02. PRN: 93 Weltweit droht der Verlust von fast 23 Mil
03.02. PRN: Gesundheitsvorsorge im Winter: Die Bedeutung

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de

Angebote der
Nutzungshinweise | Datenschutz | Impressum | Datenquellen: boerse-stuttgart.de,